Pfizer's revenue for the
three
months ended in Mar. 2026 was CHF11,376 Mil.
Its revenue for the trailing twelve months (TTM) ended in Mar. 2026 was CHF50,542 Mil.
Pfizer's Revenue per Share for the
three
months ended in Mar. 2026 was CHF1.99.
Its Revenue per Share for the trailing twelve months (TTM) ended in Mar. 2026 was CHF8.84.
Warning Sign:
Pfizer Inc revenue per share has been in decline over the past 3 years.
During the past 12 months, the average Revenue per Share Growth Rate of Pfizer was 1.10% per year.
During the past 3 years, the average Revenue per Share Growth Rate was -14.70% per year.
During the past 5 years, the average Revenue per Share Growth Rate was 2.00% per year.
During the past 10 years, the average Revenue per Share Growth Rate was 5.50% per year.
Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get other companies' revenue growth rate using Revenue per Share data.
During the past 13 years, Pfizer's highest 3-Year average Revenue per Share Growth Rate was 34.80% per year. The lowest was -14.70% per year. And the median was 6.10% per year.
Pfizer (XSWX:PFE) Revenue Explanation
In ranking the predictability, companies with more consistent revenue and earnings growth are ranked high with predictability.
Peter Lynch categorized companies according to their revenue growth:
His favorite companies are stalwart, those growing between 10-20% a year.
Companies in cyclical industries may see their revenue fluctuate wildly in good years and bad years.
Be Aware
Revenue can be manipulated by changing the way how revenue is booked. Companies may book sales before the payment is received, or before the revenue is fully earned. These will be added to balance sheet items such as account payable or account receivables.
Pfizer Revenue Related Terms
Pfizer Revenue Historical Data
* Premium members only.
The historical data trend for Pfizer's Revenue can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Drug Manufacturers - General subindustry, Pfizer's Revenue, along with its competitors' market caps and Revenue data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Pfizer Revenue vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Pfizer's Revenue distribution charts can be found below:
* The bar in red indicates where Pfizer's Revenue falls into.
Also referred as sales, revenue is income that a company receives from its normal business activities, usually from the sale of goods and services to customers. Revenue is often referred to as the "top line" due to its position on the income statement at the very top.
Revenue for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was CHF50,542 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Pfizer (XSWX:PFE) has a Revenue of CHF50,542 Mil as of Mar. 2026. Revenue is the total amount a company generates as sales through its operations. View historical data on Pfizer and its competitors.
Is Pfizer's Revenue too high?
Pfizer's current Revenue is CHF50,542 Mil. Overall, Pfizer has a GF Score™ of 59/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does Pfizer's Revenue compare to GILD and BMY?
Pfizer's Revenue of CHF50,542 Mil can be compared against companies in the Drug Manufacturers industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Revenue for a Drug Manufacturers company?
A good Revenue depends on the Drug Manufacturers industry context. However, Revenue should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Revenue mean?
A high Revenue can signal that a stock is expensive relative to its fundamentals. Revenue is the total amount a company generates as sales through its operations. View historical data on Pfizer and its competitors. Pfizer's current Revenue is CHF50,542 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Pfizer stock overvalued right now?
Based on GuruFocus' analysis, Pfizer (XSWX:PFE) is currently considered Fairly Valued. The stock's GF Value™ is CHF21.10, compared to a current price of CHF19.35 — trading 8.3% below its estimated fair value. The current Revenue is CHF50,542 Mil. Pfizer's overall GF Score™ is 59/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Revenue calculated?
Revenue is calculated from a company's financial statements. For Pfizer (XSWX:PFE), the current Revenue is CHF50,542 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Pfizer (XSWX:PFE) Overvalued in 2026?
Based on GuruFocus' analysis, Pfizer stock appears to be undervalued.
The current stock price of CHF19.35 is trading 8.3% below its estimated GF Value™ of CHF21.10.
GuruFocus considers Pfizer to be Fairly Valued.
Key valuation signals for XSWX:PFE:
Revenue: CHF50,542 Mil
GF Value™: CHF21.10 vs. price of CHF19.35 (8.3% below fair value)
No single metric tells the full story. See the XSWX:PFE stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Pfizer is one of the world's largest pharmaceutical firms, with annual sales of roughly $60 billion. While it historically sold many types of healthcare products and chemicals, now prescription drugs and vaccines account for the majority of sales. Top sellers include pneumococcal vaccine Prevnar 13 and cardiology drugs Vyndaqel and Eliquis. Pfizer sells these products globally, with international sales representing 40% of total sales. Within international sales, emerging markets are a major contributor.
59GF Score
Get the complete analysis for XSWX:PFE
Revenue is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
XSWX:PFE has been successfully added to your 
